BAMF Health Inc.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer3 trials
• Gastric and oesophageal cancer3 trials
• Prostate cancer3 trials
• Pancreatic cancer2 trials
• Childhood cancers1 trial
• High blood pressure1 trial
• Liver and biliary tract cancer1 trial
• Ovarian cancer1 trial
• Sarcoma1 trial

Phase

• Phase 12 trials
• Phase 1/22 trials
• Early phase 11 trial
• Phase 21 trial

Status

• Recruiting3 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Clarity Pharmaceuticals Ltd2 trials
• Eli Lilly and Company2 trials
• Benjamin Viglianti1 trial
• Lantheus Medical Imaging1 trial

Running trials

• Recruiting

  A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  NCT07213791· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Eli Lilly and Company· Source

• Recruiting

  64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

  NCT06298916· Phase 1/2· Lantheus Medical Imaging· Source

  Contact: Kevin Quinn

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Pancreatic cancer2 recruiting
• Childhood cancers1 recruiting
• Liver and biliary tract cancer1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Terminated

  64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

  NCT05633160· Phase 1/2· Clarity Pharmaceuticals Ltd· Source

• Completed

  64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

  NCT05407311· Phase 2· Clarity Pharmaceuticals Ltd· Source

• Recruiting

  Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

  NCT04546126· Early phase 1· Benjamin Viglianti· Source

  Contact: Jim Pool